الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 243 |  |  |
| | | from | 243 | | |
Abstract
Corona Virus disease of 2019 (COVID 19) pandemic stimulates research works to find a solution to this crisis started 2020 year till now. Bythe end of the 2021-year, severaldevelopmentsin COVID-19 pharmacotherapy have been identified. An antibody combination (Casirivimab &imdevimab)is one of new immunotherapiesagainst COVID-19. Remdesivir and favipiravir are amongantiviral therapy used against COVID-19. The aim of study was tocomparecasirivimab and imdevimab, remdesivir, and favipiravir regardingtheir efficacy to improve clinical outcomesin moderate, severe, or critical COVID-19 hospitalized patients, and to compare safety of casirivimab &imdevimab, remdesivir, and favipiravir by monitoring hypersensitivity and infusion-related reactions or anyadverse effects.